Stratesys

What we do

Who we are

What we think

Back

21 September, 2026

The pharmaceutical industry enters the era of regulated intelligence

The pharmaceutical industry is heading into 2026 under enormous pressure. Supply chain disruption, tighter regulation, international competition for biomedical innovation, the emergence of new therapies and the need to contain costs are forcing companies to review not only their technology systems, but also the way they operate.

In this context, technology has become one of the main drivers of competitiveness. But the real difference will not be between companies that adopt artificial intelligence and those that do not, but between those that simply add new tools and those that manage to integrate data, regulation, processes and people into a coherent operating model.

The sector’s digital transformation can no longer be measured by the number of platforms implemented. It must be assessed by its ability to accelerate processes, reduce errors, improve traceability, strengthen regulatory compliance and generate new ways of engaging with patients and healthcare professionals.

The AI Act changes the rules of the game

The phased application of the European AI Act will mark a turning point for the industry. Artificial intelligence is already involved in sensitive areas such as pharmacovigilance, regulatory processes, clinical research, manufacturing and quality control. That is why the regulation introduces new requirements related to transparency, traceability and systems governance.

For pharmaceutical companies, this represents a twofold challenge. On the one hand, they will have to demonstrate how the algorithms used in critical processes work, what data they operate on and what controls are in place to monitor their outcomes. On the other hand, they will need to strengthen their information governance models and establish clear accountability for the use of artificial intelligence.

However, regulation should not be interpreted solely as a barrier. It can also become an opportunity to professionalise AI adoption and steer it towards use cases with real impact.

Artificial intelligence should not act as an isolated agent that replaces processes indiscriminately, but as an enhancer of people’s productivity. Its value will lie in reducing repetitive tasks, identifying risks, improving information quality and accelerating decisions without losing human control over critical processes.

The supply chain returns to the centre of strategy

Recent years have shown that even an industry that is highly advanced from a scientific standpoint can be vulnerable to logistics disruptions.

The production and distribution of medicines requires precise coordination between manufacturing plants, logistics centres, hospitals and healthcare professionals. This complexity is even greater in areas such as vaccines or biological therapies, where any deviation can affect product availability or its storage conditions.

Artificial intelligence, advanced analytics and the internet of things make it possible to anticipate demand fluctuations, optimise inventories, improve supply chain visibility and simulate risk scenarios.

But again, the challenge is not just about implementing tools. For these models to be useful, they must be connected to the company’s production, distribution and planning systems. Logistics optimisation depends on data quality and on the ability to share data across areas that have traditionally worked separately.

From product to relationship

The transformation is also affecting the link between the pharmaceutical industry, healthcare professionals and patients.

For decades, the main channel for engaging with doctors and hospitals was the sales network. Today, that model coexists with digital interaction platforms, treatment monitoring applications, virtual assistants and omnichannel environments capable of providing up-to-date information anytime, anywhere.

This shift requires moving from a product-centred logic to one more focused on relationship and experience. Companies no longer only need to communicate the characteristics of a treatment, but also to provide useful content, facilitate access to information and support patients and professionals throughout different stages of the care pathway.

In this context, reviewing the sector’s commercial platforms is not an exclusively technological matter. The underlying debate is whether the industry will continue relying on traditional CRM models focused mainly on the relationship with the doctor, or move towards integrated engagement platforms for patients, professionals and other players in the healthcare ecosystem.

Information is the true infrastructure

All these transformations share one common element: data.

The industry generates huge volumes of information from clinical research, production, pharmacovigilance, commercial activity and patient engagement. However, in many organisations this information remains fragmented across systems that do not communicate properly.

As long as these silos persist, it will be difficult to unlock the full potential of artificial intelligence. Algorithms require reliable, integrated and contextualised information. It is not enough to have large volumes of data if there is no architecture that makes it possible to understand, connect and use it securely.

The adoption of unified information platforms must therefore become a strategic priority. Integrating structured and unstructured data enables advanced analysis, improves traceability and allows regulatory, scientific, operational and commercial decisions to be based on a more complete view of reality.

The risk of modernising without transforming

One of the main obstacles to the sector’s evolution is dependence on legacy infrastructure. Many companies are immersed in complex system upgrade and integration projects that consume a significant share of their technology investment.

The risk is modernising platforms without reviewing the operating model that supports them. If these projects are approached solely as technical upgrades, they can prolong technological debt instead of resolving it.

Before choosing a new tool, organisations should ask themselves which processes they want to transform, which decisions they need to improve, and which capabilities will be required in the coming years. Technology must respond to a business strategy, not replace it.

The most important challenge will be talent

The transformation of the pharmaceutical industry will depend not only on scientists, technologists or regulatory experts, but on professionals capable of connecting those three areas.

These hybrid profiles are scarce and increasingly in demand. Attracting and developing them will require reviewing roles, organisational models, training policies and talent value propositions.

The pharmaceutical industry is at a moment of profound disruption of its operating model. The question is no longer whether technology will transform the sector, but which companies will be able to turn artificial intelligence, information and regulatory compliance into a real competitive advantage.

The next stage will not be about digitising more. It will be about integrating better.


 

Related articles

AI and Regulation: the key factors reshaping the pharmaceutical industry

Apr 15, 2026

AI and Regulation: the key factors reshaping the pharmaceutical industry

STRATESYS identifies four priorities that will shape the sector’s agenda this year: implementation of the AI Act, logistics optimisation, a new relationship model with patients and healthcare professionals, and information integration as a productivity driver. Digital transformation in pharma is no longer only about technology adoption, but about the ability to combine traceability, regulatory compliance, operational efficiency, and new engagement models in a context of intense competitive pressure.

Agentforce World Tour Barcelona - AI applied to internal processes and conversational analytics

Mar 06, 2026

Agentforce World Tour Barcelona - AI applied to internal processes and conversational analytics

STRATESYS and MESOESTETIC present, at Agentforce World Tour Barcelona, two real cases of internal and commercial process transformation based on Salesforce, data, automation and artificial intelligence.

We celebrate the 5th edition of our Pharmaceutical Industry innovation forum

Feb 17, 2026

We celebrate the 5th edition of our Pharmaceutical Industry innovation forum

Technology and innovation executives from ALK, Avizor, BBraun, Diater, Grupo Alter, ISDIN, Laboratorios Rovi and Suanfarma, leading companies in the sector, gathered at the innovation forum organised by STRATESYS for the third consecutive year in Madrid.

Digital twins and generative AI as pillars of the transformation of the Life Sciences sector

Jan 30, 2025

Digital twins and generative AI as pillars of the transformation of the Life Sciences sector

The use of unified data platforms can cut new product discovery timelines by half. The adoption of generative artificial intelligence in regulatory and production processes is expected to reduce quality deviations by up to 40%, improving competitiveness

Read more